REFERENCES
- US FDA. FDA guidance for industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Federal Drug and Food Administration, Rockville, MD 2002
- Kees F, Farber L, Bucher M, Mair G, Morike K, Grobecker H. Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. Br J Clin Pharmacol 2001; 52: 705–707, [PUBMED], [INFOTRIEVE]
- Ramesh M, Mamidi RN, Jagannath K, Singh SK, Rao KS, Rao YK, Seshagirirao C, Rajagopalan R, Srinivas NR. Oral bioavailability and pharmacokinetics of DRF-4367, a new COX-2 inhibitor in rats. Eur J Drug Metab Pharmacokinet 2003; 28: 137–141, [PUBMED], [INFOTRIEVE]
- Sasaki K, Yonebayashi S, Yoshida M, Shimizu K, Aotsuka T, Takayama K. Improvement in the bioavailability of poorly absorbed glycyrrhizin via various non-vascular administration routes in rats. Int J Pharm 2003; 265: 95–102, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Nicolaos G, Crauste-Manciet S, Farinotti R, Brossard D. Improvement of cefpodoxime proxetil oral absorption in rats by an oil-in-water submicron emulsion. Int J Pharm 2003; 263: 165–171, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wang F, Jiang X, Lu W. Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats. Int J Pharm 2003; 263: 1–7, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Zhang Q, Jiang X, Jiang W, Lu W, Su L, Shi Z. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int J Pharm 2004; 27(5)85–96, [CROSSREF]
- Mao S, Chen J, Wei Z, Liu H, Bi D. Intranasal administration of melatonin starch microspheres. Int J Pharm 2004; 272: 37–43, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Jansen M, Darby I, Abribat T, Dubreuil P, Ferdinandi ES, Hardy JG. Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. Int J Pharm 2004; 276: 75–81, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bosquillon C, Préat V, Vanbever R. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J Control Rel 2004; 96: 233–244, [CROSSREF]
- Khoo SM, Porter CJH, Charman WN. The formulation of Halofantrine as either non-solubilising PEG6000 or solubilising lipid based solid dispersions: Physical stability and absolute bioavailability assessment. Int J Pharm 2000; 205: 65–78, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Nave R, Bethke TD, Marle SPv, Zech K. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet 2004; 43: 479–486, [PUBMED], [INFOTRIEVE]
- Chu S-Y, Deaton R, Cavanaugh J. Absolute Bioavailability of Clarithromycin after Oral administration in Humans. Antimicrob Agents Chemother 1992; 36: 1147–1150, [PUBMED], [INFOTRIEVE]
- Chittick GE, Gillotin C, McDowell JA, Lou Y, Edwards KD, Prince WT, Stein DS. Abacavir: Absolute Bioavailability, Bioequivalence of Three Oral Formulations, and Effect of Food. Pharmacotherapy 1999; 19: 932–942, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wade M, Baker FJ, Roscigno R, DellaMaestra W, Hunt TL, Lai AA. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. J Clin Pharmacol 2004; 44: 83–88, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz E. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 2003; 25: 2822–2835, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Mariappan TT, Singh S. Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat. Int J Tuberc Lung Dis 2003; 7: 897–903
- Sankar R, Sharda N, Singh S. Behaviour of decomposition of rifampicin in the presence of isoniazid in the pH range 1-3. Drug Dev Ind Pharm 2003; 29: 733–738, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bhutani H, Mariappan TT, Singh S. Physical and chemical instability anti-TB fixed-dose combination products (FDCs) under accelerated climatic conditions. Int J Tuberc Lung Dis 2004; 8: 1073–1080, [PUBMED], [INFOTRIEVE]
- Mariappan TT, Singh S. Evidence of efflux mediated and saturable absorption of rifampicin in rat intestine using ligated loop and everted sac techniques. Molecular Pharmaceutics 2004; 1: 363–367, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Acocella G, Bonollo L, Mainardi M, Margaroli P, Tenconi LT. Serum and urine concentrations of rifampicin administered by intravenous infusion in man. Arzneim-Forsch 1977; 27: 1221–1226
- Loos U, Musch E, Jensen JC, Schwabe HK, Eichelbaum M. Influence of the enzyme induction by rifampicin on its presystemic metabolism. Pharmac Ther 1987; 33: 201–204, [CROSSREF]
- Koup JR. Pharmacokinetic of rifampicin in children. II: Oral bioavailability. Ther Drug Monit 1986; 8: 17–22, [PUBMED], [INFOTRIEVE]
- Sweeny RW, Divers TJ, Bensen C. Pharmacokinetics of rifampicin in calves and adult sheep. J Vet Pharmacol Ther 1988; 11: 413–416
- Jernigan AD, Jean GDS, Rings M, Sams RA. Pharmacokinetics of rifampicin in adult sheep. Am J Vet Res 1991; 52: 1626–1629, [PUBMED], [INFOTRIEVE]
- Kohn CW, Sams R, Kowalske JJ. Pharmacokinetics of single intravenous and single and multiple oral administration of rifampicin in mars. J Vet Pharmacol Ther 1993; 16: 119–131, [PUBMED], [INFOTRIEVE]
- Zhang JN, Liu XG, Zhu M, Chiu FCK, Li RC. Assessment of presystemic factors on the oral bioavailability of rifampicin following multiple dosing. J Chemother 1998; 10: 354–359, [PUBMED], [INFOTRIEVE]
- Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003; 52: 981–986, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2004; 58: 265–278, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Saito H, Tomioka H. Therapeutic efficacy of liposome-entrapped rifampicin against Mycobacterium avium complex infection induced in mice. Antimicrob Agents Chemother 1989; 3: 429–433
- Prakash J, Velpandian T, Pandey JN, Gupta SK. Serum rifampicin levels in patients with tuberculosis: Effects of p-glycoprotein and CYP3A4 blockers on its absorption. Clin Drug Invest 2003; 23: 463–472
- Pandey R, Zahoor A, Sharma S, Khuller GK. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis 2003; 83: 373–378, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Tse FLS. Pharmacokinetics in drug discovery and development: Non-clinical studies. Pharmacokinetics-Regulatory-Industrial-Academic Perspectives, PG Welling, FLS Tse. Marcel Dekker, Inc, New York 1995; 281–334
- Panchagnula R, Agrawal S, Ashokraj Y, Varma MVS, Sateesh K, Bhardwaj V, Bedi S, Gulati I, Parmar J, Kaul CL, Blomberg B, Fourie B, Roscignio G, Wire R, Laing R, Evans P, Moore T. 2003. Fixed dose combination for tuberculosis: Lessons learned from a clinical, formulation and regulatory perspective. Methods Find Exp Clin Pharmacol 2004; 26: 703–721, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Agarwal S, Panchagnula R. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations. Int J Pharm 2004; 287: 97–112, [CROSSREF]